Humanigen Inc. (NASDAQ: HGEN) stock fell -6.08% on Wednesday to $0.14 against a previous-day closing price of $0.15. With 0.97 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.45 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1549 whereas the lowest price it dropped to was $0.1437. The 52-week range on HGEN shows that it touched its highest point at $6.66 and its lowest point at $0.13 during that stretch. It currently has a 1-year price target of $3.50. Beta for the stock currently stands at -1.01.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HGEN was down-trending over the past week, with a drop of -14.06%, but this was down by -0.62% over a month. Three-month performance dropped to -53.01% while six-month performance fell -92.97%. The stock lost -97.61% in the past year, while it has lost -96.14% so far this year. A look at the trailing 12-month EPS for HGEN yields -1.52 with Next year EPS estimates of -0.38. For the next quarter, that number is -0.12. This implies an EPS growth rate of -66.90% for this year and 56.10% for next year. EPS is expected to grow by 12.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 21.90%.
Float and Shares Shorts:
At present, 119.08 million HGEN shares are outstanding with a float of 104.84 million shares on hand for trading. On Oct 30, 2022, short shares totaled 6.53 million, which was 6.30% higher than short shares on Sep 29, 2022. In addition to Dr. Cameron Durrant M.D., MBA as the firm’s Chairman, CEO, Principal Financial & Accounting Officer, Dr. Dale Chappell M.B.A., M.D., MBA serves as its Chief Scientific Officer & Director.
Through their ownership of 6.12% of HGEN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 17.12% of HGEN, in contrast to 17.12% held by mutual funds. Shares owned by individuals account for 1.63%. As the largest shareholder in HGEN with 11.71% of the stake, Black Horse Capital Management LL holds 12,134,287 shares worth 12,134,287. A second-largest stockholder of HGEN, GSA Capital Partners LLP, holds 1,026,643 shares, controlling over 0.99% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in HGEN, holding 933,874 shares or 0.90% stake. With a 0.66% stake in HGEN, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 682,358 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.26% of HGEN stock, is the second-largest Mutual Fund holder. It holds 273,613 shares valued at 38306.0. iShares Tr. – Micro Cap ETF holds 0.12% of the stake in HGEN, owning 119,912 shares worth 16788.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, HGEN reported revenue of $1.04M and operating income of -$29.35M. The EBITDA in the recently reported quarter was -$29.38M and diluted EPS was -$0.43.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HGEN since 4 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HGEN analysts setting a high price target of $9.00 and a low target of $0.50, the average target price over the next 12 months is $3.50. Based on these targets, HGEN could surge 6328.57% to reach the target high and rise by 257.14% to reach the target low. Reaching the average price target will result in a growth of 2400.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. HGEN will report FY 2022 earnings on 03/28/2023. Analysts have provided yearly estimates in a range of -$0.90 being high and -$1.33 being low. For HGEN, this leads to a yearly average estimate of -$1.06. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Humanigen Inc. surprised analysts by -$0.05 when it reported -$0.23 EPS against a consensus estimate of -$0.18. The surprise factor in the prior quarter was -$0.11. Based on analyst estimates, the high estimate for the next quarter is -$0.02 and the low estimate is -$0.31. The average estimate for the next quarter is thus -$0.12.
Summary of Insider Activity:
Insiders traded HGEN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 2,107,496 while 0 shares were sold.